{"database": "openregs", "table": "documents", "rows": [["FDA-1995-S-0039-0321", "FDA", "FDA-1995-S-0039", "Attachment 1 - Shah, et al., An Open Clinical Pilot Study to Evaluate the Safety and Efficacy of Natto Kinaseas an Add-on Oral Fibrinolytic Agent Tolow Molecular Weight Heparin & Anti-Plateletsin Acute Ischeamic Stroke\" re NDI 631, Nattolife/Nattokinase Enzyme from Zytech Biotech PVT LTD", "Supporting & Related Material", "Background Material", "2014-02-28T05:00:00Z", 2014, 2, null, null, "2016-08-15T20:52:33Z", null, 0, 0, "0900006480c36026"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-1995-S-0039-0321"], "units": {}, "query_ms": 0.4808849189430475, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}